A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Inclusion Criteria: * Subjects must be between the ages of 18 and 78 years, inclusive. * Histologically confirmed multiple myeloma expected to receive high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) * Received ≥3 cycles but ≤6 cycles of daratumumab-based quadruplet induction therapy (quadruplet induction therapy: combining daratumumab, a proteasome inhibitor, an IMiD, and dexamethasone) before ASCT * At least one week (7 days) from last induction cycle prior to the first dose of G-CSF for mobilization * The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR) * ECOG performance status 0 or 1 * Adequate organ function at screening as defined below: * White blood cell (WBC) counts \> 2.5 × 10\^9/L * Absolute neutrophil count \> 1.5 K/cumm * Platelet count \>100 K/cumm * GFR value of ≥15 mL/min/1.732 (by MDRD equation) * ALT and/or AST ≤2.5 × ULN * Total bilirubin ≤2.0 × ULN unless the participant has Gilbert disease * INR or PT: ≤1.5 × ULN unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants * aPTT: ≤1.5 × ULN unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants. * Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative urine …